Miragen Therapeutics, Inc. (MGEN) Expected to Post Earnings of -$0.32 Per Share

Equities research analysts expect Miragen Therapeutics, Inc. (NASDAQ:MGEN) to report earnings per share of ($0.32) for the current quarter, Zacks reports. Two analysts have made estimates for Miragen Therapeutics’ earnings. The highest EPS estimate is ($0.28) and the lowest is ($0.41). Miragen Therapeutics reported earnings of ($7.72) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 95.9%. The business is scheduled to report its next quarterly earnings results on Friday, March 23rd.

According to Zacks, analysts expect that Miragen Therapeutics will report full-year earnings of ($1.35) per share for the current fiscal year, with EPS estimates ranging from ($1.62) to ($0.98). For the next year, analysts anticipate that the firm will post earnings of ($1.44) per share, with EPS estimates ranging from ($1.72) to ($1.29). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Miragen Therapeutics.

A number of research firms have recently commented on MGEN. Oppenheimer began coverage on Miragen Therapeutics in a research note on Friday, January 12th. They set an “outperform” rating and a $13.00 target price on the stock. B. Riley assumed coverage on Miragen Therapeutics in a research note on Friday, January 5th. They issued a “buy” rating and a $15.50 price objective on the stock. Chardan Capital restated a “buy” rating on shares of Miragen Therapeutics in a research note on Tuesday, January 16th. Cann assumed coverage on Miragen Therapeutics in a research note on Friday, January 12th. They issued an “outperform” rating and a $13.00 price objective on the stock. Finally, Zacks Investment Research upgraded Miragen Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 price objective on the stock in a research note on Friday, November 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $16.46.

In related news, Director Bruce Booth purchased 545,454 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The shares were purchased at an average cost of $5.50 per share, for a total transaction of $2,999,997.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Adam Scott Levy purchased 9,090 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The shares were bought at an average price of $5.50 per share, for a total transaction of $49,995.00. Following the completion of the transaction, the insider now owns 10,540 shares of the company’s stock, valued at $57,970. The disclosure for this purchase can be found here. Insiders own 44.40% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN increased its position in shares of Miragen Therapeutics by 203.8% during the fourth quarter. Wells Fargo & Company MN now owns 17,804 shares of the medical research company’s stock valued at $185,000 after buying an additional 11,943 shares during the period. Seaward Management Limited Partnership bought a new stake in shares of Miragen Therapeutics during the third quarter valued at about $117,000. Russell Investments Group Ltd. bought a new stake in shares of Miragen Therapeutics during the third quarter valued at about $147,000. Bank of New York Mellon Corp increased its position in shares of Miragen Therapeutics by 67.1% during the fourth quarter. Bank of New York Mellon Corp now owns 45,775 shares of the medical research company’s stock valued at $478,000 after buying an additional 18,374 shares during the period. Finally, BSW Wealth Partners bought a new stake in shares of Miragen Therapeutics during the third quarter valued at about $203,000. Hedge funds and other institutional investors own 22.59% of the company’s stock.

Miragen Therapeutics (NASDAQ:MGEN) traded up $0.02 during midday trading on Tuesday, hitting $5.61. The stock had a trading volume of 253,049 shares, compared to its average volume of 383,897. Miragen Therapeutics has a 12 month low of $5.01 and a 12 month high of $18.00. The company has a current ratio of 7.11, a quick ratio of 7.11 and a debt-to-equity ratio of 0.04.

WARNING: “Miragen Therapeutics, Inc. (MGEN) Expected to Post Earnings of -$0.32 Per Share” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://stocknewstimes.com/2018/02/18/miragen-therapeutics-inc-mgen-expected-to-post-earnings-of-0-32-per-share.html.

Miragen Therapeutics Company Profile

Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.

Get a free copy of the Zacks research report on Miragen Therapeutics (MGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply